Custom-Made vaccine trial offers new hope for aggressive lung cancer
NCT ID NCT04397003
Summary
This study is testing whether a personalized vaccine, designed from a patient's own tumor, can help the immune system fight cancer when given alongside an immunotherapy drug (durvalumab). It aims to see if this combination is safe, feasible to make, and can help control the disease longer in people with extensive-stage small cell lung cancer. The trial is for adults who are starting their first treatment for this type of cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.